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692Objective: The purpose of the present study was to compare the selection criteria and short-term outcomes
among 3 prospective clinical trials using stereotactic body radiotherapy (Radiation Therapy Oncology Group
[RTOG] trial 0236), sublobar resection (American College of Surgeons Oncology Group [ACOSOG] trial
Z4032), and radiofrequency ablation (ACOSOG trial Z4033).
Methods: The selection criteria and outcomes were compared among RTOG 0236 (n ¼ 55), ACOSOG Z4032
(n ¼ 211), and ACOSOG Z4033 (n ¼ 51). Age, Eastern Cooperative Oncology Group performance status, per-
centage of predicted forced expiratory volume in 1 second, and percentage of predicted carbon monoxide dif-
fusing capacity of the lung were used to perform a propensity-matched analysis among patients with clinical
stage 1A in RTOG 0236 and ACOSOG Z4032.
Results: The patients in ACOSOG Z4033 undergoing radiofrequency ablation were older (75.6 7.5 years) than
those in RTOG0236 (72.5 8.8 years) and ACOSOGZ4032 (70.2 8.5 years;P¼ .0003). The pretreatment per-
centage of predicted forced expiratory volume in 1 secondwas 61.3% 33.4% for RTOG0236, 53.8% 19.6%
for ACOSOG Z4032, and 48.8%  20.3% for ACOSOG Z4033 (P ¼ .15). The pretreatment percentage of pre-
dicted carbon monoxide diffusing capacity of the lung was 61.6%  30.2% for RTOG 0236, 46.4%  15.6%
for ACOSOG Z4032, and 43.7% 18.0% for ACOSOG Z4033 (P¼ .001). The overall 90-day mortality for ste-
reotactic body radiotherapy, surgery, and radiofrequency ablationwas 0%, 2.4% (5/211), and 2.0% (1/51), respec-
tively (P¼ .5). Overall, the unadjusted 30-day grade 3þ adverse events weremore commonwith surgery thanwith
stereotactic body radiotherapy (28% vs 9.1%, P¼ .004), although no difference was between the 2 groups at 90
days. Among the patients with clinical stage IA inACOSOGZ4032, 29.3% had amore advanced pathologic stage
at surgery. A propensity-matched comparison showed no difference between stereotactic body radiotherapy and
surgery for 30-day grade 3þ adverse events (odds ratio, 2.37; 95% confidence interval, 0.75-9.90; P ¼ .18).
Conclusions: Among appropriately matched patients, no difference was seen in early morbidity between sub-
lobar resection and stereotactic body radiotherapy. These results underscore the need for a randomized trial to
delineate the relative survival benefit of each modality and to help stratify patients considered high risk.
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The Journal of Thoracic and Cardiovascular SurgThe reference standard for treatment of stage I non–small
cell lung cancer (NSCLC) in operable patients is surgical
resection with lobectomy and systematic lymph node eval-
uation. However, a significant number of patients with stage
I lung cancer are considered medically inoperable or high-
risk surgical candidates.1,2 In an aging population,
pulmonary insufficiency and cardiac comorbidities could
preclude surgery or place patients at significant risk of
complications after surgery. Although surgery has been
the mainstay of therapy for high-risk patients, the evolution
of nonsurgical therapies, such as stereotactic body radio-
therapy (SBRT) and radiofrequency ablation (RFA), have
raised the issues of patient selection, treatment-related mor-
bidity, and the relative oncologic efficacy of each therapy.
Before the development of SBRT and RFA, patients con-
sidered at high risk or unsuitable for lobectomy wereery c March 2013
Abbreviations and Acronyms
ACOSOG ¼ American College of Surgeons
Oncology Group
AEs ¼ adverse events
DLCO% ¼ percentage of predicted carbon
monoxide diffusing capacity of the
lung
FEV1% ¼ percentage of predicted forced
expiratory volume in 1 second
NSCLC ¼ non–small cell lung cancer
PFT ¼ pulmonary function test
RFA ¼ radiofrequency ablation
RTOG ¼ Radiation Therapy Oncology Group
SBRT ¼ stereotactic body radiotherapy
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Sgenerally offered surgery with sublobar resection. In these
patients with marginal lung function, sublobar resection is
potentially advantageous because of the preservation of
lung function.3,4 Single-center studies have shown a de-
crease in local recurrence rates for patients undergoing sub-
lobar resection with the addition of brachytherapy
compared with sublobar resection alone (17.2%-18.6%
vs 2%-3.3%).5,6 Because of these data, a phase III
randomized controlled trial (American College of
Surgeons Oncology Group [ACOSOG] trail Z4032) was
developed that randomized patients with stage I NSCLC
to either sublobar resection or sublobar resection with
brachytherapy.7 The local recurrence data and disease-
related survival should become availablewithin 1 to 2 years.
RFA and SBRT have been used with increasing fre-
quency in the medically inoperable and high-risk popula-
tion with early-stage NSCLC. In small series of patients
undergoing RFA, the 2-year survival has ranged from
57% to 78% among patients with early-stage NSCLC.8-11
A phase II prospective nonrandomized trial examining
high-risk patients with stage I NSCLC using RFA (ACO-
SOG Z4033) has completed accrual, but the survival and
recurrence data have not yet matured.
In contrast to conventional fractionated radiotherapy,
SBRT provides a high dose per fraction to the tumor distrib-
uted within a few fractions,3-5 creating an ablative
mechanism for tumor destruction, while the steep dose
gradients help to avoid damage to the surrounding
parenchyma and other structures. Studies of SBRT in
medically inoperable and some operable patients with
early-stage NSCLC have reported relatively low local recur-
rence rates, ranging from 3% to 20%, depending on the
delivered biologic effective dose, length of follow-up, and
definition of local failure.12-21 Given the comorbidity in
this population, overall survival is often expectedly modest,
ranging from 32% to 57% at 3 years in single-center studies.
A subsequent phase II North American trial of SBRTThe Journal of Thoracic and Ca(Radiation Therapy Oncology Group [RTOG] 0236) re-
vealed a 3-year disease-free and overall survival of 48%
and 56%, respectively, in patients with stage I NSCLC
who had been deemed inoperable by a surgeon or pulmonol-
ogist.22 These data prompted the comparative study of SBRT
and surgery in high-risk operable patients with early-stage
NSCLC (ACOSOG Z4099/RTOG 1021). The latter trial
only recently opened and results are years away. Aswe begin
to integrate this new technology into the treatment of
NSCLC, it will be important for us to have a clear
understanding of the selection criteria, relative treatment-
related morbidity and mortality, and oncologic efficacy.
The present retrospective study was designed to compare
the entrance criteria, short-term outcomes, and early
changes in pulmonary function tests (PFTs) among 3 clinical
trials using sublobar resection (ACOSOG Z4032), SBRT
(RTOG 0236), and RFA (ACOSOG Z4033) in the high-
risk and inoperable patient population with early-stage
NSCLC. A comparison of the entrance criteria among these
studies was performed to show a spectrum of comorbidity
across each study and to identify potential overlap among
the studies. Propensity matching was used to compare the
short-term outcomes, morbidity, and mortality.
Understanding the current selection criteria and relative
comorbidities in each cohort could help us to establish an ob-
jective risk stratification system in the future to guide us in
selection of therapy for this challenging patient population.
METHODS
The present study was a retrospective secondary analysis of prospec-
tively collected data from 3 multicenter clinical trials. The data were for-
mally requested from the RTOG and ACOSOG, and the analysis was
approved by both organizations. The institutional review board atWashing-
ton University School of Medicine also approved the present study. From
these data, we compared the pretreatment (baseline) characteristics, includ-
ing demographic data, pulmonary function, and other comorbidities, when
available. PFTs included the percentage of predicted forced expiratory vol-
ume in 1 second (FEV1%) and percentage of predicted carbon monoxide
diffusing capacity of the lung (DLCO%) measured preoperatively and 90
days after treatment completion. The disease of all patients was clinically
staged using chest computed tomography (CT) and fluorodeoxyglucose-
positron emission tomography.
RTOG 0236 was a phase II, multicenter, North American trial examining
the efficacy of SBRT in patients with stage I NSCLC who were considered
medically inoperable. The study, opened in2004, enrolled59 patients to com-
plete accrual, andmidterm survival data have been published for 55 evaluable
patients.22 The primary endpoint was local control, with secondary endpoints
of treatment-related toxicity, disease-free survival, overall survival, and pat-
terns of failure. The patients received 3 fractions of 20Gy eachwithin 8 to 14
days. The patients were considered inoperable based on the evaluation find-
ings from a thoracic surgeon or pulmonologist (Table 1). The prospectively
collected PFT data were incomplete and were supplemented post hoc after
a retrospective chart review. All data regarding pretreatment comorbidity
provided by the RTOG were included in the synopsis of the results.
ACOSOG Z4032 was a randomized phase III trial comparing sublobar
resection and sublobar resection plus brachytherapy in patients with stage I
NSCLC who were considered too high risk for surgery. The study was
closed to accrual in January 2010 after a planned enrollment of 222 evalu-
able patients. The primary outcome measure was the interval to localrdiovascular Surgery c Volume 145, Number 3 693
TABLE 1. Criteria for medically inoperable or high-risk surgical
patients from recent clinical trials of surgery or radiotherapy
Criteria for medically inoperable patients undergoing SBRT
(RTOG 0236)
Required
Patient deemed medically inoperable by an experienced thoracic cancer
clinician (thoracic surgeon or pulmonologist)
Suggested criteria for medical inoperability
FEV1<40% predicted
Postoperative FEV1<30% predicted
Severely reduced DLCO
Hypoxemia
Hypercapnia
VO2<50% predicted
Severe pulmonary hypertension
Diabetes mellitus with severe end organ damage
Severe cerebral, cardiac, or peripheral vascular disease
Severe chronic heart disease
Criteria for high-risk surgical patient undergoing sublobar resection
(ACOSOG Z4032) or RFA (ACOSOG Z4033)
Required
1 Major or 2 minor criteria
Major criteria
FEV1<50% predicted
DLCO<50% predicted
Minor criteria
Age>75
FEV1 or DLCO 50%-60%
Pulmonary hypertension (PA systolic>40 mm Hg)
LV function<40%
PaO2<55 mm Hg
PCO2>45 mm Hg
For Z4033—additional criterion
Deemed not a candidate for sublobar resection by an
ACOSOG-approved surgeon
SBRT, Stereotactic body radiotherapy; RTOG, Radiation Therapy Oncology Group;
FEV1, forced expiratory volume in 1 second; DLCO, carbon monoxide diffusing
capacity of lung; VO2, peak oxygen uptake; ASOSOG, American College of Surgeons
OncologyGroup;RFA, radiofrequency ablation;PA, pulmonary artery; LV, left ventric-
ular;PaO2, partial pressure of arterial oxygen;PCO2, partial pressureof carbondioxide.
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Srecurrence. The secondary outcome measures included morbidity, overall
and failure-free survival, regional or distant recurrence, quality of life,
and pulmonary function. The initial results with early treatment-related
morbidity and mortality have been published, but the primary endpoints
have not yet matured. Because the primary endpoint has not yet been pub-
lished, for the purposes of the present study, the surgical patients were
considered2 as 1 cohort without stratifying according to the use of brachy-
therapy. Based on predefined entrance criteria for this retrospective study
of patients with clinical T1-2N0 disease, 1 patient from the ACOSOG
Z4032 trial was ineligible for this comparison. In the previously published
results of short-term outcomes from Z4032, all registered patients were in-
cluded regardless of eligibility as long as they had received sublobar resec-
tion or sublobar resection plus brachytherapy in an intent-to-treat analysis.7
This excluded patient was classified in the database as clinical N2 and thus
did not meet the critieria for entrance into our retrospective comparison of
the 3 treatment modalities. The comorbidity and PFT data were collected
prospectively, and predefined objective entrance criteria were used to de-
fine the high-risk patient (Table 1). Adverse events (AEs) were recorded us-
ing the Common Terminology Criteria for Adverse Events, version 3.0.23694 The Journal of Thoracic and Cardiovascular SurgWithin each category of AEs, a description of severity or grade is included.
Grade 1 is mild, grade 2, moderate, grade 3, severe, grade 4, life-
threatening or disabling, and grade 5, death related to the AE.
The primary objective for ACOSOG Z4033 was the 2-year survival in
high-risk patients with stage IA NSCLC undergoing RFA. Additional out-
come measures included local, regional, and distant recurrence and
procedure-related morbidity and mortality after RFA. The study completed
accrual of 54 patients in July 2010. The primary endpoint data are still ma-
turing and have not yet been published. Additionally, information on AEs
has not yet been published. The entry criteria for Z4033 were identical to
those of Z4032, with the additional criterion that patients should be evalu-
ated by an ACOSOG-approved surgeon and deemed not a candidate for
sublobar resection. The eligibility criteria are also outlined in Table 1.
The initial comparisons of the entry criteria and short-term outcomes
were performed with the raw data from all 3 clinical trials. Categorical
data were compared using the chi-square test and continuous data using
the Kruskal-Wallis test. Data are reported as the mean  standard devia-
tion, unless otherwise stated.
Subsequent comparisons were performed specifically between RTOG
0236 and ACOSOG Z4032 for patients with clinical stage T1 tumors. Be-
cause of the ongoing randomized trial comparing SBRTand sublobar resec-
tion (ACOSOG Z4099/RTOG 1021), this additional matched comparison
focused on the SBRT and sublobar resection patients, excluding the RFA
patients from the subgroup analysis. Once the primary endpoints for
Z4033 have been published and the long-term outcomes are available for
all 3 studies, a comparative analysis of all 3 modalities will be performed.
A propensity score was built for patients with clinical stage T1 tumors us-
ing age, performance score, FEV1%, and DLCO%. The propensity scores
were developed to estimate the adjusted risks of short-term outcomes asso-
ciated with the choice of treatment (SBRT or surgery). Logistic regression
analysis was used to estimate the probability of trial choice, given the listed
risk factors. Patients were classified into 5 equal-size propensity score
groups among the patients with complete data (groups 1-5). This analysis
included 32 patients from RTOG 0236 and 202 patients from ACOSOG
Z4032. Conditional logistic regression analysis with 5 strata for categorical
variables and repeated measures analysis of variance with the strata as a re-
peated factor for continuous outcomes was used to compare the outcomes
between the 2 studies. In all cases, the P values were 2-sided.RESULTS
There were 55 evaluable patients in the RTOG 0236
study (SBRT), 211 in the ACOSOG Z4032 study (sublobar
resection), and 51 in the ACOSOG Z4033 study (RFA). The
basic demographics and tumor characteristics are listed in
Table 2. The RFA patients were older than the SBRT and
sublobar resection patients. The SBRT patients had superior
DLCO% than the sublobar resection and RFA patients. The
patients had clinical stage T1 or T2 disease in all 3 studies.
The tumor size from CTwas not available for RTOG 0236
but was similar between Z4032 and Z4033 (P ¼ .7). Of the
T2 tumors, 11 (20%) were in the SBRT study, 3 (1.4%) in
the sublobar resection study, and none in the RFA study. All
patients had clinical stage N0 and M0 according to the CT
and positron emission tomography findings.
The SBRT patients received a total dose of 60  0.2 Gy
(range, 58.2-60 Gy). The mean length of treatment for the
SBRT patients was 8.1  2.9 days (range, 4-24 days). The
operative time for the sublobar resection patients was
2.2  1.0 hours, and the hospital length of stay was
6.5  5.8 days (range, 0-41 days). No pathologic stagingery c March 2013
TABLE 2. Pretreatment demographics and comorbidity profiles for RTOG 0236, ACOSOG Z4032, and ACOSOG Z4033
Pretreatment characteristics RTOG 0236 (SBRT) ACOSOG Z4032 (sublobar resection) ACOSOG Z4033 (RFA) P value
Patients (n) 55 211 51
Mean age (y) 72.5  8.8 70.2  8.5 75.6  7.5 .0003*
Age>75 y 21 (38.9) 79 (37.4) 30 (58.8) .02y
Women (n) 34 (61.8) 117 (55.5) 28 (54.9) .7
ECOG 1-2 43 (78.1) 169 (80.1) 42 (82.4) .86
Race (white) 51 (92.7) 199 (94.3) 44 (86.3) .02z
Clinical stage 1A 44 (80) 208 (98.6) 51 (100) <.0001x
Pulmonary hypertension NR 5 (2.4) 1 (2.0) .86
Poor LV function NR 12 (5.7) 6 (11.8) .12
MMRC dyspnea score NR 46 (21.8) 12 (23.5) .79
pO2 55 mm Hg or SpO2 88% 2 (3.7) 10 (4.7) 1 (2.0) .66
pCO2>45 mm Hg 8 (14.8) 6 (2.8) 0 .0002{
DLCO% 61.6  30.2 46.4  15.6 43.7  18.0 .001jj
FEV1% 61.3  33.4 53.8  19.6 48.8  20.3 .15
FVC% 79.8  23.2 74.8  17 NR .4
Data presented as mean SD or n (%). P values from chi-square or Kruskal-Wallis test. RTOG, Radiation Therapy Oncology Group; ACOSOG, American College of Surgeons
Oncology Group; RFA, radiofrequency ablation; ECOG, Eastern Cooperative Oncology Group; NR, not reported; LV, left ventricular;MMRC,Modified Medical Research Coun-
cil; pO2, partial pressure of oxygen; SpO2, saturation of peripheral oxygen; pCO2, partial pressure of carbon dioxide;DLCO%, percentage of predicted carbon monoxide diffusing
capacity of lung; FEV1%, percentage of predicted forced expiratory volume in 1 second; FVC%, percentage of forced vital capacity; SBRT, stereotactic body radiotherapy.
*P< .0001, Z4032 vs Z4033. yP ¼ .04, RTOG 0236 vs Z4033; P ¼ .005, Z4032 vs Z4033. zP ¼ .04, RTOG 0236 vs Z4032. xP< .0001 RTOG vs Z4032; P ¼ .0007,
RTOG 0236 vs Z4033. {P ¼ .0004, RTOG 0236 vs Z4032; P ¼ .004, RTOG 0236 vs Z4033. jjP ¼ .0008 RTOG 0236 vs Z4032; P ¼ .001, RTOG 0236 vs Z4033.
Crabtree et al General Thoracic Surgery
G
T
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ologic stage for all patients undergoing sublobar resection
was pIA in 70.1%, pIB in 25%, IIA in 0.5%, IIB in 1.6%,
IIIA in 1.1%, IIIB in 0.5%, and IV in 1.1%. A total of 27 pa-
tients (12.8%) had no documented nodal pathologic assess-
ment after surgery. This included 14 with T1NxM0, 6 with
T2NxM0, 1 with T3NxM0, and 6 with missing T, N, or M
stage data.
The 30- and 90-daymortality andmorbidity, including the
AE data, for each study are listed in Table 3. For the RFA
study, information on mortality only was available. In the
RFA cohort, 1 treatment-related death occurred. The patientTABLE 3. Comparison of mortality and post-treatment adverse
events
Variable
RTOG
0236
(SBRT)
ACOSOG Z4032
(sublobar
resection)
ACOSOG
Z4033
(RFA)
P
value*
Patients (n) 55 211 51
30-d Overall
mortality
0 3 (1.4) 1 (2.0) .6
90-d Overall
mortality
0 5 (2.4) 2 (3.9) .5
Treatment-related
mortality
0 0 1 (2.0) .07
Grade 3þ AEs at 30 d 5 (9.1) 59 (28.0) NR .004
Grade 5 AEs at 30 d 0 3 (1.4) NR .37
Grade 3þ AEs at 90 d 12 (21.8) 70 (33.2) 14 (27.5) .24
Grade 5 AEs at 90 d 0 6 (2.8) 2 (3.9) .38
Data in parentheses are percentages. RTOG, Radiation Therapy Oncology Group;
ACOSOG, American College of Surgeons Oncology Group; RFA, radiofrequency ab-
lation; AEs, adverse events; NR, not reported; SBRT, stereotactic body radiotherapy.
*Chi-square test.
The Journal of Thoracic and Cadied of pneumonitis 30 to 90 days after treatment. No patient
had died at 90 days in the SBRT study. In the sublobar resec-
tion group, 5 patients had died at 90 days after surgery.7 Two
patients died of a cerebrovascular accident and pulmonary
embolus and another died of cardiopulmonary arrest within
30 days. Three additional deaths had occurred at 30 to 90
days: 1 patient died of cancer progression, 1 was a cardiac-
related death, and 1 patient died of sepsis.7 The grade 5
AEs for sublobar resection included 1 prolonged air leak,
1 stroke, 1 aspiration event, 1 cardiac-related event, 1TABLE 4. Strata 1-5 created for propensity-matched comparison of
RTOG 0236 and ACOSOG Z4032 in patients with stage IA NSCLC
Strata 1-5 RTOG 0236 ACOSOG Z4032 P value
Strata 1
Patients (n) 4 42
Median age (y) 66 70 .57
ECOG 1-2 (n) 2 (50) 36 (86) .14
DLCO (%) 28 30 .4
FEV1 (%) 25 39 .016
90-d Grade 3þ AEs 1 (25) 20 (48) 1.0
Strata 5
Patients (n) 13 34
Median age (y) 74 73 .5
ECOG 1-2 9 (70) 24 (71) 1.0
DLCO 83 69 .03
FEV1 79 56 .036
90-d Grade 3þ AEs 3 (23) 8 (24) 1.05
Data in parentheses are percentages. Strata 2-4 will be included in an Appendix.
RTOG, Radiation Therapy Oncology Group; ACOSOG, American College of Sur-
geons Oncology Group; ECOG, Eastern Cooperative Oncology Group; DLCO, car-
bon monoxide diffusing capacity of the lung; FEV1, forced expiratory volume in 1
second; AEs, adverse events; NSCLC, non–small cell lung cancer.
rdiovascular Surgery c Volume 145, Number 3 695
FIGURE 1. A, Pretreatment and post-treatment (90-day) comparison of
percentage of predicted forced expiratory volume in 1 second (FEV1%) be-
tweenZ4032 andRadiationTherapyOncologyGroup (RTOG) 0236. For pa-
tients in Z4032, FEV1% was 6.4% greater than that in the RTOG 0236
subjects at follow-up after adjusting for baseline FEV1% (P¼ .024). B, Pre-
treatment and post-treatment (90-day) comparison of percentageof predicted
carbon monoxide diffusing capacity of the lung (DLCO%) between Z4032
and Radiation Therapy Oncology Group (RTOG) 0236. No difference
were seen in the change in DLCO% in patients treated with stereotactic
body radiotherapy (SBRT) and those treated with surgery in Z4032
(P ¼ .92). ACOSOG, American College of Surgeons Oncology Group.
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RFA included 1 pneumonitis and 1 sudden death. Complica-
tions related to pretreatment biopsy such as pneumothorax
were not included as AEs for any of the studies.
A propensity analysis was performed to compare SBRT
and sublobar resection in patients with T1 lesions, similar
to the planned comparison in the new, ongoing randomized
trial comparing SBRTand surgery (ACOSOGZ4099/RTOG
1021). There were 208 sublobar resection patients with T1
lesions, of whom 202 had baseline PFT data available for
the propensity-based analysis. Therewere 44 SBRT patients
with T1 lesions, of whom32 had baseline PFT data available
for the propensity-based analysis. The primary endpoints in-
cluded the 30-day and 90-day 3þ AEs. Age, Eastern Coop-
erative Oncology Group performance score, preoperative
FEV1%, and DLCO% were used to build a propensity
score. From the propensity analysis, no difference was
seen in the 30-day (odds ratio, 2.37; 95% confidence inter-
val, 0.75-9.90; P ¼ .18) or 90-day (odds ratio, 1.92; 95%
confidence interval, 0.71-6.08; P ¼ .25) grade 3þ AEs.
The patients were classified into 5 groups: 32 from the
SBRT study and 202 from the sublobar resection study.
Within stratum 1 for sublobar resection (n¼ 42), themedian
age was 70 years, the median DLCO% was 30%, and the
median FEV1%was 39%. In this stratum, the 90-day grade
3þ AE rate was 48%, with a 90-day mortality of 2.4%. In
contrast, within strata 5 for sublobar resection (n¼ 34), me-
dian age was 73 years, DLCO%was 69% and FEV1%was
56%. Within this stratum, the 90-day grade 3þAE rate was
24%, with no mortality at 90 days (Table 4).
An additional analysis was performed examining pulmo-
nary function before and after treatment between the SBRT
and sublobar resection groups for DLCO% and FEV1% us-
ing repeated measures analysis of variance with the strata as
a repeated factor and the baseline PFT as a covariate. Post-
treatment values were collected 90 days after surgery or
SBRT completion. Figure 1 outlines the pre- and post-
treatment DLCO% and FEV1% for these studies. No dif-
ference was seen in the change in DLCO% in patients
treated with SBRT versus surgery (P ¼ .92). For the sublo-
bar resection patients, after adjustment, the FEV1% was
6.4% greater than that in the SBRT subjects at follow-up,
after adjusting for the baseline FEV1% (P ¼ .024).
DISCUSSION
Although the standard of care for treatment of early-stage
NSCLC in low- tomoderate-risk patients remains lobectomy
with systematic lymph node assessment, the classification
and treatment selection of the inoperable or high-risk popu-
lation ismore challenging.Historically, the treatment options
were less efficacious for medically inoperable patients until
the advent or application of SBRT for earlyNSCLC.Conven-
tional external beam radiotherapy was associated with poor
survival and significant morbidity.24-29 For the high-risk696 The Journal of Thoracic and Cardiovascular Surgsurgical population, sublobar resection offered the only via-
ble treatment option in these patients, but significant risk was
often incurred. The evaluation of these data have shown no
short-termmortality for SBRT, with 90-day overall mortality
of 2.4% and 2% for surgery and RFA, respectively. Contem-
porary perioperative mortality for lobectomy is 0.8% to
2.0% in a low- to moderate-risk group of patients.30-32
Many experienced thoracic surgeons now favor minimally
invasive or video-assisted thoracic surgery approach because
of the associated decrease in morbidity and length of stay
compared with standard thoracotomy, which was the ap-
proach for most patients in ACOSOG Z4032.32-35 The
treatment-relatedmortality rate of 2.0% forRFA in theACO-
SOG Z4033 trial is consistent with that from other small se-
ries with procedure-related mortality of 1.5% to 2.6%.36,37
The pending results from ACOSOG Z4033 should help toery c March 2013
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RFA and help define the role of RFA in this setting.
Regarding treatment-related morbidity, in an unmatched
comparison, 90-day AEs were more common with surgery
than with SBRT. In a matched comparison using regression
analysis and propensity matching, no difference was seen in
30- and 90-day AE rates between the treatment modalities.
Several factors should be considered in this comparison of
outcomes. Most surgical complications are acute or sub-
acute, occurring within the first 30 to 90 days. Some com-
plications of SBRT, such as pain, rib fracture, radiation
pneumonitis, or a decline in pulmonary function, can occur
several months or years after treatment and were not ac-
counted for with this short-term analysis. For all these trials,
the lesions were selected because of their peripheral loca-
tion, excluding stage I tumors that were deeper within the
parenchyma. Treatment of more central lesions with sur-
gery, SBRT, and RFA is associated with greater
procedure-related morbidity compared with the peripheral
lesions.12,37-39 From a surgical perspective, these more
central lesions would likely require more complex
sublobar resection or lobectomy with the associated loss
of more functional lung parenchyma and thus a potential
increase in morbidity. Most importantly, these short-term
data should ultimately be compared within the context of
the relative efficacy of the treatment modality on overall
and disease-free survival after longer follow-up.
Although some objective criteria are available that can
help define the high-risk or inoperable group of patients,
these criteria are often debated, and, in many cases, this
assessment is subjective. Examination of the available
PFT data for the inoperable patient undergoing SBRT in
RTOG0236would suggest that many of these patients could
have been considered surgical candidates, albeit, high risk,
and could have been offered surgery or SBRT. Given the
mean preoperative FEV1% of 65% and DLCO% of 64%
in the RTOG 0236 stage T1 patients, the perception of
most experienced thoracic surgeons according to the data
presented would be to recommend surgical resection and,
possibly, lobectomy in the absence of other obvious comor-
bidities. It is much more complicated than this, because pul-
monary insufficiency might not account for all patients
deemed medically inoperable in the SBRT-treated group.40
In previous retrospective studies of SBRT, treatment-
related morbidity was inversely related to FEV1 and
DLCO.40 The implication is that patients with good pulmo-
nary function are often poor surgical candidates because of
other nonpulmonary comorbidities. These nonpulmonary-
related comorbid factors such as heart disease might be
poor prognostic indicators in this population. Thus, the sub-
jective classification of inoperability by a surgeon or pulmo-
nologist does not allow for an objective assessment of
operability and for comprehensive comparisons between
studies. The factors identified in multivariate models asThe Journal of Thoracic and Cathe predictors ofmorbidity andmortality for lung cancer sur-
gery include FEV1, DLCO, performance status (Zubrod and
EasternCooperativeOncologyGroup scales), American So-
ciety of Anesthesiology ratings, renal dysfunction, steroid
use, body mass index, age, diabetes, male gender, and dysp-
nea scores (Medical Research Council classification).41-44
These parameters should be documented in any trial of
high-risk or inoperable patients. Furthermore, we should es-
tablish a risk stratification score using these parameters to
define the predictive mortality and morbidity for patients
to guide trial development and treatment selection in lieu
of evolving nonsurgical therapies for high-risk patients
with early-stage NSCLC.
Some critics of ACOSOG Z4032 have suggested that the
entrance criteria are too broad, allowing for inclusion of
healthier, nonhigh-risk patients. There does appear, how-
ever, to be a subset of high-risk patients with incrementally
greater surgical morbidity relative to other patients in the
trial. The 90-day AE rate doubled from quintile 1
(FEV1%, 56%; DLCO%, 69%; 90-day 3þ AE rate,
24%) to quintile 5 (FEV1%, 39%; DLCO%, 30%; 90-
day 3þ AE rate, 48%). These data do not suggest that we
should abandon the use of sublobar resection in high-risk
patients. It would, however, suggest that there might be
equipoise between SBRT and surgery to support the neces-
sary inclusion into a randomized trial. Other retrospective,
propensity-matched, comparative studies of SBRT and sur-
gery have suggested a relatively high morbidity and mortal-
ity rate in the surgical cohort. In the surgery cohorts
matched to the high-risk or inoperable patients undergoing
SBRT, the procedure-related mortality was 7% to 8.3%
compared with 0% to 1.7% for the SBRT cohort.18,45,46
These data would again suggest that there is a subset of
high-risk patients offered surgery who might have prohibi-
tively high morbidity and mortality, creating an opportunity
to examine alternative less-invasive therapies.
There are other factors to consider regarding the role of
SBRT versus surgery in this population. In ACOSOG
Z4032, 29.3% of clinical stage I patients were ultimately
staged at a greater pathologic stage at surgery. In other
reports of patients with clinical stage I NSCLC, 35%
were ultimately found to have a greater pathologic stage
at surgery, with 13.8% having occult stage N1 disease
and 3.5% occult N2 disease.18 Subsequent chemotherapy
was given to 21% of patients upstaged with surgery, but
none of the SBRT patients received adjuvant therapy.46
Nonetheless, nodal failure was only encountered in 2 of
55 patients in the RTOG 0236.22 Multiple factors have
been proposed to explain this discrepancy between nodal
detection in the surgical series and a relative lack of nodal
failure with SBRT, including the inadequacy of detecting
clinical nodal failure and the peripheral radiation dose.
The proportion of patients with nodal upstaging was lower
in Z4032 (1.4% stage N1 and 1.4% stage N2) comparedrdiovascular Surgery c Volume 145, Number 3 697
General Thoracic Surgery Crabtree et al
G
T
Swith other reports, and this might have been related to a ret-
icent approach to nodal dissection in this high-risk group
undergoing sublobar resection. In the ACOSOG Z4032,
12.8% of patients had no documented nodal assessment
at surgery. Failure to systematically assess for nodal disease
at surgery, even within the context of a sublobar resection in
high-risk patients, negates the benefit of surgical identifica-
tion of occult nodal disease and precludes the use of adju-
vant therapy. These data reiterate the inadequacy of
clinical staging with positron emission tomography/CT
and suggest that a poorly executed sublobar resection
with inadequate assessment of margins and without system-
atic nodal dissection might not provide superior outcomes
compared with alternative tumor ablation technologies.
Although the data are limited, the relative preservation of
pulmonary function in the surgically treated group compared
with the SBRT patients is perhaps an unanticipated finding
for some. The proponents of SBRToften cite the preservation
of lung function as an advantageover surgery. Surgical series,
however, have shown good preservation of pulmonary func-
tion after sublobar resection.3,4 Additionally, the lung
volume reduction achieved by resection in those with
localized emphysema might contribute to this finding. The
present study was inherently limited by the retrospective
comparison of these cohorts in small, presumably different,
populations. Additional exclusion of SBRT patients
because of incomplete pulmonary function data might also
have obscured the comparative results, given the small
sample size. It is likely that patients deemed inoperable
because of nonpulmonary comorbidities were less likely
to undergo PFTs. This might have excluded a more ill
subset of SBRT patients for the comparison because
nonpulmonary, cardiac-related morbidity might portend
a worse outcome in this population. Many of these issues
will be addressed in the ongoing cooperative group study,
ACOSOG Z4099/RTOG 1021. This phase III randomized
multi-institutional trial examines the role of sublobar resec-
tion versus SBRT in the treatment of high-risk patients with
stage I NSCLC. The primary objective is the 3-year overall
survival, and secondary objectives include locoregional re-
currence, disease-free survival, AEs, PFTs, and cost and
quality of life comparisons. These trial results will be crucial
in helping us identify the relative efficacy of these treatments
in the high-risk population and repudiate or affirm current as-
sumptions made about the relative role of each treatment
modality.
I would like to thank Donna Vernaci and Jennifer Bell for their
assistance with formatting and preparation of this study.
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Radiat Oncol Biol Phys. 2010;78:S15.NTARYThe best that surgery has to offerThomas A. D’Amico, MDThe treatment of patients with stage I lung cancer con-
tinues to be examined through decades of controversy:lobectomy versus sublobar resection, minimally invasive
strategies versus open approaches, and most recently the
use of nonsurgical interventions versus resection. Each of
these debates pivots on the competing principles of optimiz-
ing oncologic efficacy while minimizing invasiveness and
complications. Although the Lung Cancer Study Group es-
tablished lobectomy as the standard of care for clinical stage
I lung cancer,1 those findings are being challenged by trials
demonstrating equivalent results with segmentectomy in
selected patients2 and currently being tested again in
a prospective, randomized trial (Cancer and Leukemia
Group B 140503).3 More clearly established is therdiovascular Surgery c Volume 145, Number 3 699
